The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo

Nicotine and Tobacco Research

Volumn 5, Issue 6, 2003, Pages 891-899

  Sellers, Edward M ^a,b,c,e   Ramamoorthy, Yamini ^a   Zeman, Marilyn V ^a   Djordjevic, Mirjana V ^d   Tyndale, Rachel F ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d AMERICAN HEALTH FOUNDATION   (United States)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARBON MONOXIDE; CARCINOGEN; COTININE; CYTOCHROME P450 2A6; CYTOCHROME P450 INHIBITOR; GLUCURONIDE; METHOXSALEN; NICOTINE; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; CATARACT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG URINE LEVEL; ENZYME INHIBITION; EXPIRED AIR; FEMALE; HUMAN; IN VIVO STUDY; MALE; PHOTOSENSITIVITY; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CARCINOGENS; FEMALE; GANGLIONIC STIMULANTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOXSALEN; MIXED FUNCTION OXYGENASES; NICOTINE; NITROSAMINES; PLACEBOS; SMOKING;

EID: 0347599059     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622200310001615231     Document Type: Article

References (48)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Nemoto, N., Sato, K., & Kamataki, T. (2002). Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiology, Biomarkers and Prevention, 11(9), 890-894.
3. Benowitz, N. L., Jacob, P., & Savanapridi, C. (1987). Determinants of nicotine intake while chewing nicotine polacrilex gum. Clinical Pharmacology and Therapeutics, 41, 467-473.
4. Benowitz, N. L., Zevin, S., & Jacob, P. (1997). Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. British Journal of Clinical Pharmacology, 43(3), 259-267.
5. Carmella, S. G., Akerkar, S. A., Richie, J. P., & Hecht, S. S. (1995). Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiology Biomarkers & Prevention, 4(6), 635-642.
6. Carmella, S. G., Kagan, S. S., & Hecht, S. S. (1993). Evidence that a hemoglobin adduct used for dosimetry of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a carboxylic ester. Environmental Health Perspectives, 99, 203-205.
7. Fujeida, M., Yamazaki, H., Dosaka-Akita, H., Sawamura, Y., Kunitoh, H., & Kamataki, T. (2002, Month). Relationship between CYP2A6*7 and lung cancer risk. Presentation at the 14th International Symposium on Microsomes and Drug Oxidation, Sapporo, Japan.
8. Gu, D. F., Hinks, L. J., Morton, N. E., & Day, I. N. (2000). The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Annals of Human Genetics, 64(Pt. 5), 383-390.
9. Hariharan, M., VanNoord, T., & Greden, J. F. (1988). A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clinical Chemistry, 34(4), 724-729.
10. Hecht, S. S. (1998). Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Research in Toxicology, 11(6), 559-603.
11. Hecht, S. S. (1999). DNA adduct formation from tobacco-specific N-nitrosamines. Mutation Research, 424(1-2), 127-142.
12. Hecht, S. S., & Hoffmann, D. (1989). The relevance of tobacco-specific nitrosamines to human cancer. Cancer Survey, 8(2), 273-294.
13. Hecht, S. S., Trushin, N., Reid-Quinn, C. A., Burak, E. S., Jones, A. B., Southers, J. L., Gombar, C. T., Carmella, S. G., Anderson, L. M., & Rice, J. M. (1993). Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: Pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis, 14(2), 229-236.
14. Kharasch, E. D., Hankins, D. C., & Taraday, J. K. (2000). Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metabolism and Disposition, 28(1), 28-33.
15. Klech, H. (1998). Reduced smoking - an acceptable goal for the hopeless heavy smoker? European Respiratory Journal, 11, 263-264.
16. Kushida, H., Fujita, K., Suzuki, A., Yamada, M., Endo, T., Nohmi, T., & Kamataki, T. (2000). Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis, 21(6), 1227-1232.
17. Larsen, K. (1972). Clinica Chimica Acta, 41, 209-211.
18. Law, M. R., Morris, J. K., Watt, H. C., & Wald, N. J. (1997). The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. British Journal of Cancer, 75(11), 1690-1693.
19. Loriot, M. A., Rebuissou, S., Oscarson, M., Cenee, S., Miyamoto, M., Ariyoshi, N., Kamataki, T., Hemon, D., Beaune, P., & Stucker, L. (2001). Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics, 11(1), 39-44.
20. Maser, E., Richter, E., & Friebertshauser, J. (1996). The identification of 11 beta-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone. European Journal of Biochemistry, 238(2), 484-489.
21. McMorrow, M. J., & Foxx, R. M. (1983). Nicotine's role in smoking: An analysis of nicotine regulation. Psychological Bulletin, 93(2), 302-327.
22. Messina, E. S., Tyndale, R. F., & Sellers, E. M. (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 282(3), 1608-1614.
23. Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N., & Kamataki, T. (1999). CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochemical and Biophysical Research Communications, 261(3), 658-660.
24. Monbaliu, J. G., Rosseel, M. T., & Bogaert, M. G. (1981). Analysis of methoxsalen in plasma by reversed-phase high-performance liquid chromatography. Journal of Pharmaceutical Sciences, 70(8), 965-966.
25. Murphy, S. E., Johnson, L. M., & Pullo, D. A. (1999). Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chemical Research in Toxicology, 12(7), 639-645.
26. Nakajima, M., Kwon, J. T., Tanaka, N., Zenta, T., Yamamoto, Y., Yamamoto, H., Yamazaki, H., Yamamoto, T., Kuroiwa, K., & Yokoi, T. (2001). Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clinical Pharmacology and Therapeutics, 69(1), 72-78.
27. Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., & Kuroiwa, Y. (1996a). Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metabolism and Disposition, 24(11), 1212-1217.
28. Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., & Kuroiwa, Y. (1996b). Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277(2), 1010-1015.
29. Nowell, S., Sweeney, C., Hammons, G., Kadlubar, F. F., & Lang, N. P. (2002). CYP2A6 activity determined by caffeine phenotyping: Association with colorectal cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 11(4), 377-383.
30. Oscarson, M., Gullsten, H., Rautio, A., Bernal, M. L., Sinues, B., Dahl, M. L., Stengard, J. H., Pelkonen, O., Raunio, H., & Ingelman-Sundberg, M. (1998). Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Letters, 438(3), 201-205.
31. Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q. Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., & Pelkonen, O., et al. (1999). Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Letters, 448(1), 105-110.
32. Patten, C. J., Smith, T. J., Murphy, S. E., Wang, M. H., Lee, J., Tynes, R. E., Koch, P., & Yang, C. S. (1996). Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Archives of Biochemistry and Biophysics, 333(1), 127-138.
33. Rao, Y., Hoffmann, E., Zia, M., Bodin, L., Zeman, M., Sellers, E. M., & Tyndale, R. F. (2000). Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking. Molecular Pharmacology, 58(4), 747-755.
34. Russel, M. S. H. (1987). SAS/STAT user's guide. In W. R. Martin, G. R. Vauhon, E. T. Iwamoto, & L. David (Eds.). Advances in Behavioral Biology (pp. 25-50). New York: Plenum.
35. Schmid, J., Prox, A., Zipp, H., & Koss, F. W. (1980). The use of stable isotopes to prove the saturable first-pass effect of methoxsalen. Biomedical Mass Spectrometry, 7(11-12), 560-564.
36. Sellers, E. M., Kaplan, H. L., & Tyndale, R. F. (2000). Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics, 68(1), 35-43.
37. Smith, T. J., Guo, Z., Guengerich, F. P., & Yang, C. S. (1996). Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis, 17, 809-813.
38. Sweeney, C., Coles, B. F., Nowell, S., Lang, N. P., & Kadlubar, F. F. (2002). Novel markers of susceptibility to carcinogens in diet: Associations with colorectal cancer. Toxicology, 181-182, 83-87.
39. Tan, W., Chen, G., Xing, D., Song, C., Kadlubar, F., & Lin, D. (2001). Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. International Journal of Cancer, 95, 96-101.
40. Tietz, N. W. (1981). Fundamentals of clinical chemistry (pp. 981-999). Philadelphia: Saunders.
41. Tiihonen, J., Pesonen, U., Kauhanen, J., Koulu, M., Hallikainen, T., Leskinen, L., & Salonen, J. T. (2000). CYP2A6 genotype and smoking. Molecular Psychiatry, 5, 347-348.
42. Tsukino, H., Kuroda, Y., Qiu, D., Nakao, H., Imai, H., & Katoh, T. (2002). Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. International Journal of Cancer, 100(4), 425-428.
43. Tyndale, R. F., Kaplan, H. L., Zhang, W., & Sellers, E. M. (2000, Month). Society for Research on Nicotine and Tobacco.
44. Upadhyayam, P., Kenney, P. M., Hochalter, J. B., Wang, M., & Hecht, S. S. (1999). Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis, 20(8), 1577-1582.
45. Warner, K., Slade, J., & Sweanor, J. T. (1997). The emerging market for long-term nicotine maintenance. The Journal of the American Medical Association, 278(13), 1087-1092.
46. Yamazaki, H., Chiba, I., Topcu, Z., Fujeida, M., Shibata, T., Ariyoshi, N., Sevgican, F., Muthumala, M., Kobayashi, H., & Kamataki, T. (2002, Month). CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers. Presentation at the 14th International Symposium on Microsomes and Drug Oxidation, Sapporo, Japan.
47. Yamazaki, H., Inui, Y., Yun, C. H., Guengerich, F. P., Shimada, T. (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13(10), 1789-1794.
48. Zhang, W., Kilicarslan, T., Tyndale, R. F., & Sellers, E. M. (2001). Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition, 29(6), 897-902.